The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet

About this update from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H

[{"type":"text","content":"CHENGDU, China, May 29, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱®) in combination with pembrolizumab (KEYTRUDA®[1], MSD's anti-programmed cell death protein 1 (PD-1) antibody) as first-line treatment for Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS)≥1% non-small cell lung cancer (NSCLC), was presented as an oral presentation by Professor Caicun Zhou from Shanghai East Hospital, Tongji University (Abstract #8506, Lung Cancer – Metastatic Non-Small Cell).","length":816,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":312,"url":"https://media.zenfs.com/en/prnewswire.com/517dd83c78eb7daea36bb64b32ef2a37"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iCG8L.qVOCmopA9DvGrrOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTU1MA--/https://media.zenfs.com/en/prnewswire.com/517dd83c78eb7daea36bb64b32ef2a37","width":400,"height":312},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/7caiSaHJVhTF1yWep1cYDA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQ5OQ--/https://media.zenfs.com/en/prnewswire.com/517dd83c78eb7daea36bb64b32ef2a37","width":400,"height":312}},"href":"https://mma.prnewswire.com/media/2991285/image1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Sac-TMT is designed with a unique, bifunctional linker and differentiated belotecan-derivative payload. The linker is conjugated via cysteine, which maximizes payload delivery to tumor cells both through its irreversible connection with the high-affinity and targeting anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a moderately toxic novel topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4.","length":466,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":229,"url":"https://media.zenfs.com/en/prnewswire.com/e61d9f2b...

More updates from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H